

1719 E. Walnut St Pasadena, CA 91106 Phone 626-798-6789 Fax 626-798-8376

## PCSK9 Inhibitor (PRALUENT / REPATHA) - ENROLLMENT FORM

PATIENT INFORMATION						
Name (First, Last):					_	
	Date of Birth					
	PI FASF FAX	COPY OF INSU	IRANCE CARD, CHART	NOTES AND I ABS	•	
Medication			SIG	NOTES AND EADS	·	Refills
Wedication	Dose/Strength		316		Quantity	Reillis
□ PRALUENT	□ 75 mg PEN INJ □ 150 mg PEN INJ	,	dose subcutaneously e dose (300 mg total) eve	•	□ 2 pens	
□ REPATHA (Sureclick Pen)			dose subcutaneously every 2 weeks		□ 2 pens	
□ REPATHA (Pushtronix)			ose once monthly		□ 3.5 ml (1 device)	
					l	
Diagnosis (ICD10):			Previously tried/fa	iled therapies	& dates:	
<ul> <li>□ Prevent and reduce the risk of future ASCVD events. (No ICD10 listed)</li> <li>□ E78.5 Hyperlipidemia, Unspecified</li> <li>□ Z78.9 Statin Intolerance</li> <li>□ I25.10 Cardiovascular disease, unspecified</li> <li>□ I20.9 Angina Pectoris, Unspecified</li> <li>□ I73.9 Peripheral vascular disease, unspecified</li> <li>□ Z82.49 Family history of ischemic heart disease and other diseases of the circulatory system</li> <li>□ Z95.5 Presence of coronary angioplasty implant and graft stent</li> <li>□ I25.2 Old myocardial infarction</li> <li>□ E78.01 Familial hypercholesterolemia</li> <li>□ M62.82 Rhabdomyolysis</li> <li>□ □</li> <li>□ M62.82 Rhabdomyolysis</li> </ul>		□ Crestor □ Lipitor □ Pravastatin □ Simvastatin □ Zetia □ Niacin □ Cholestyramine □ Colestipol □ Dicyclomine □ Hyoscyamine □ Tricyclic Antidepre □ SSRI □ Clonidine □ Other Therapies	Date:/ Date:/			
Total # of Dangerou	is Drugs Prescribed					
		PRESCRIBE	ER'S INFORMATION			
Prescriber Name (First.	Last):			NPI #:		
						<del></del>
	Fax: (					

I authorize 986 Specialty Pharmacy and its representatives to act as an agent to initiate and execute the insurance prior authorization process

IMPORTANT NOTICE: This facsimile is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.